1st Quarter - Report

GSK (FKA GLAXOSMITHKLINE INC.) for GSK (FKA GLAXOSMITHKLINE INC.)

Firm
Client
Income
—
Expenses
$1,700,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

H.R. 2617: Consolidated Appropriations Act, 2023 (PL. 117-328) H.R. 5376: Inflation Reduction Act of 2022 (P.L. 117-169) H.R. 6833: Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 - User fee reauthorization (P.L. 117-180) S. 4543: James M. Inhofe National Defense Authorization Act for Fiscal Year 2023 H.R. ____: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 H.R. ____: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 H.R.___: National Defense Authorization Act for Fiscal Year 2024 S._____: National Defense Authorization Act for Fiscal Year 2024 S._____: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 S. ____: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 FY 2024 Presidents Budget Request

LobbyistCovered position, as disclosed
MICHAEL J CALVO —
MONICA CLOUD —
AMY CHEVALIER EFANTIS —
ALEC RUBIO HINOJOSA —
CURTIS E RHYNE —
PHILIP M THEVENET —

Contacted: HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); SENATE

Bills named: S. 4543 (118th), H.R. 6833 (118th), H.R. 5376 (118th), H.R. 2617 (118th)

Copyright/Patent/Trademark CPT

S. 79: Interagency Patent Coordination and Improvement Act of 2023 - This bill establishes the Interagency Task Force on Patents to support coordination and communication between the U.S. Patent and Trademark Office (PTO) and the Food and Drug Administration (FDA) on activities relating to patents for human drugs and biological products. S. 142: Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements S. 150: Affordable Prescriptions for Patients Act of 2023 - Provisions related to intellectual property and patents S. 574: Increasing Prescription Drug Competition Act - Patent-related policy issues Biopharmaceutical innovation and patent policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues Patent use codes policy issues

LobbyistCovered position, as disclosed
MICHAEL J CALVO —
MONICA CLOUD —
AMY CHEVALIER EFANTIS —
ALEC RUBIO HINOJOSA —
CURTIS E RHYNE —
PHILIP M THEVENET —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Patent & Trademark Office (PTO)

Bills named: S. 79 (118th), S. 142 (118th), S. 574 (118th), S. 150 (118th)

Health Issues HCR

H.R. 198: Drug Pricing Transparency and Accountability Act - Provisions related to the 340B Program H.R. 382: Pandemic is Over Act - This bill terminates the COVID-19 public health emergency that was declared on January 31, 2020, on the date of the bill's enactment H.R. 4121, PRO Seniors Act, provisions related to drug rebates Protecting American Innovation Act, provisions related to intellectual property PDUFA Riders provisions related to disclosure of trade secrets H.R. 4390: Protect 340B Act - Provision related to 340B Program H.R. 5376: Inflation Reduction Act of 2022 (P.L. 117-169) H.R. 7032: Increasing Transparency in Generic Drug Application Act - This bill requires the Food and Drug Administration to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). S. 148: Stop STALLING Act - Provisions related to citizen petitions S. 315: Taxpayer Research And Contributions Knowledge Act of 2023 or TRACK Act of 2023 - To direct the Secretary of Health and Human Services and other Federal officials to compile into a searchable database information relating to Federal support for biomedical research and development, and for other purposes. S. 898: Fair Accountability and Innovative Research Drug Pricing Act of 2021 - Provisions related to drug pricing S. 2076: PASTEUR Act of 2021 - Provisions related to antimicrobial resistance policy issues S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act or PREVENT Pandemics Act Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) Cancer Moonshot Initiative21st Century Cures 2.0 Drug cost and pricing policy issues Principles for drug pricing reform Drug importation policy issues Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance (AMR) policy issues High deductible health plans/HSA policy issues Supply chain and foreign manufacturing policy issues Real world evidence policy issues Clinical trial diversity policy issues Prescription drug abuse policy issues 340B Drug Pricing Program - drug discount program policy issues Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues COVID-19 policy issues Pandemic preparedness policy issues Defense Production Act policy issues

LobbyistCovered position, as disclosed
MICHAEL J CALVO —
MONICA CLOUD —
AMY CHEVALIER EFANTIS —
ALEC RUBIO HINOJOSA —
CURTIS E RHYNE —
PHILIP M THEVENET —

Contacted: SENATE; Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: S. 898 (118th), H.R. 4121 (118th), S. 3799 (118th), H.R. 4390 (118th), H.R. 198 (118th), S. 2076 (118th), S. 148 (118th), H.R. 7032 (118th), H.R. 382 (118th), S. 315 (118th), H.R. 5376 (118th)

Medicare/Medicaid MMM

H.R. 485: Protecting Health Care for All Patients Act of 2023 - This bill prohibits all federal health care programs, including the Federal Employees Health Benefits Program, and federally funded state health care programs (e.g., Medicaid) from using prices that are based on quality-adjusted life years (i.e., measures that discount the value of a life based on disability) to determine relevant thresholds for coverage, reimbursements, or incentive programs. H.R. 830: Help Ensure Lower Patient Copays Act or the HELP Copays Act - This bill requires health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. H.R. 5376: Inflation Reduction Act of 2022 (P.L. 117-169) S. 127: Pharmacy Benefit Manager Transparency Act of 2023 - Provisions related to PBMs National coverage determination policy issues Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Rebate policy issues Pharmacy Benefit Manager reform and policy issues Value-based purchasing arrangements policy issues Center for Medicare and Medicaid Innovation (CMMI) and model policy issues Medicaid rebates and waiver policy issues CMS Guidance on the Medicare Drug Price Negotiation Program: Initial Memorandum [ ] IPAY 2026 and Solicitation of Comments CMS Guidance on Medicare Part B and D Inflation Rebates

LobbyistCovered position, as disclosed
MICHAEL J CALVO —
MONICA CLOUD —
AMY CHEVALIER EFANTIS —
ALEC RUBIO HINOJOSA —
CURTIS E RHYNE —
PHILIP M THEVENET —

Contacted: Health & Human Services, Dept of (HHS); SENATE; Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES

Bills named: H.R. 5376 (118th), H.R. 830 (118th), H.R. 485 (118th), S. 127 (118th)

Trade (domestic/foreign) TRD

H.R. 4376, USTRx Act, provisions related to establishing a Chief Pharmaceutical Trade Negotiator S. 113: Prescription Pricing for the People Act of 2023 - Provisions related to medical supply chains and prescription drug pricing transparency S. 2495: Protecting our Pharmaceutical Supply Chain from China Act of 2021 - Provisions related to medical supply chains Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues

LobbyistCovered position, as disclosed
MICHAEL J CALVO —
MONICA CLOUD —
AMY CHEVALIER EFANTIS —
ALEC RUBIO HINOJOSA —
SHIRA KILCOYNE —
CURTIS E RHYNE —
PHILIP M THEVENET —

Contacted: SENATE; U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES

Bills named: H.R. 4376 (118th), S. 113 (118th), S. 2495 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.